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ABSTRACT		The	international	society	for	pharmacoeconomics	and	outcomes	research	(ISPOR)	defines	“Pharmacoeco-nomics	as	the	field	of	study	that	evaluates	the	behaviour	of	individuals,	firms	and	markets	relevant	to	the	use	of	pharmaceutical	products,	services	and	programs	and	which	frequently	focuses	on	the	costs	(inputs)	and	consequences	(outcomes)	of	that	use”.	It	is	the	description	and	analysis	of	the	cost	of	drug	therapy	to	health	care	systems	and	society.	This	prospective	observation	study	was	carried	out	for	over	a	period	of	6	months	commencing	from	March	2014	to	August	2014	among	inpatients	of	General	medicine	and	Nephrol-ogy	departments	of	a	tertiary	care	referral	hospital	in	kerala.All	diabetes	mellitus	patient	treated	in	the	In-patient	department	of	General	medicine	and	Nephrology	department	during	March-August	2014	were	mon-itored,	collect	relevant	data	and	entered	into	the	data	sheet.	Based	on	the	inclusion	and	exclusion	criteria	of	the	protocol	approved	by	the	IEC,	patients	belonging	to	the	age	group	40-70	of	both	sex	were	selected	and	enrolled	for	the	study.	 	 	
Keywords:	ISPOR;	COI;	HbA1C;	RBS.	
INTRODUCTION	The	 international	 society	 for	 pharmacoeconomics	and	outcomes	research	(ISPOR)	defines	“Pharmaco-economics	as	the	field	of	study	that	evaluates	the	be-haviour	of	individuals,	firms	and	markets	relevant	to	the	use	of	pharmaceutical	products,	services	and	pro-grams	and	which	frequently	focuses	on	the	costs	(in-puts)	and	consequences	(outcomes)	of	that	use”.	It	is	
the	description	and	analysis	of	the	cost	of	drug	ther-apy	to	health	care	systems	and	society.	 	Cost	of	illness	(COI)	evaluation	is	also	known	as	bur-den	of	disease.	 It	 is	an	economic	evaluation	method	used	to	identify	and	estimate	the	overall	cost	of	a	par-ticular	 disease	 for	 a	 defined	 population.	 It	 involves	measuring	 the	direct	and	 indirect	costs	attributable	to	a	specific	disease.	Direct	cost	is	the	obvious	cost	ie,	the	cost	of	 the	health	service.	 It	 includes	physicians	fees,	 cost	 of	 administering	 the	medication,	 costs	 of	treating	an	adverse	drug	reaction,	cost	of	drugs,	sup-plies,	 laboratory	 tests	 etc.	 Indirect	 cost	 is	 the	 one	borne	 by	 the	 patient	 and	 family	 Eg.	 Cost	 of	 travel/	transportation,	 expenses	 incurred	 on	 accommoda-tion	needed	near	the	treatment	center,	on	food,	fam-ily	care,	loss	of	family/	patient	income	due	to	absen-teeism	from	work.	It	includes	lost	productivity	from	a	disease	like	wages	and	salaries	lost	due	to	morbidity,	loss	of	earnings,	and	loss	of	leisure	time.	COI	evalua-tion	is	not	used	to	compare	competing	treatment	pro-grams	or	treatment	alternatives.	It	is	used	to	provide	an	 estimation	 of	 the	 financial	 burden	 or	 economic	load	of	a	disease.	It	estimates	the	maximum	amount	that	could	potentially	be	saved	or	gained	if	a	disease	was	eradicated.	Numerous	cost	of	illness	studies	have	been	 conducted	 since	 1970s	 throughout	 the	 world	highlighting	the	influence	of	the	magnitude	of	the	im-pact	of	 illness	on	society.	They	are	 limited	 in	deter-mining	 how	 resources	 are	 to	 be	 allocated	 because	
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they	do	not	measure	benefits.	An	estimate	of	costs	is	often	 useful,	 however,	 when	 considering	 planning,	decision-making,	and	regulatory	development.	Cost-of-illness	studies	are	used	most	often	by	policymak-ers,	 governmental	 and	 nongovernmental	 organiza-tions,	researchers,	and	pharmaceutical	companies.	The	cost	of	 illness	study	of	diabetes	mellitus	is	very	important	in	the	present	situation	because	the	prev-alence	and	complication	of	diabetes	is	increases	day	by	day	 .Diabetes	mellitus	 is	a	chronic	and	non-com-municable		disease	that	is	widespread.	It	is	the	fourth	or	 fifth	 leading	 cause	of	 death	 in	most	high	 income	countries.	 Diabetes	 is	 undoubtedly	 one	 of	 the	most	challenging	health	problems	of	the	21st	century.	Ac-cording	to	IDF	diabetic	atlas	6th	edition	2014	about	8.3%	of	adults	 ie,	382	million	people	have	diabetes,	and	the	number	of	people	with	the	disease	 is	set	 to	rise	beyond	592	million	by	2035.About	80%	 live	 in	low	and	middle	income	countries.	The	greatest	num-ber	of	people	with	diabetes	is	between	40-59	years	of	age.	Yet,	with	175	million	of	cases	currently	undiag-nosed,	a	vast	amount	of	people	with	diabetes	are	pro-gressing	 towards	 complications	unawares.	Diabetes	caused	5.1	million	deaths	in	2013.	Every	six	seconds	a	person	dies	from	diabetes.	Peoples	with	type	2	dia-betes	can	remain	undiagnosed	for	many	years,	una-ware	of	the	long	term	complication	such	as	micro	and	macrovascular	 complications	 being	 caused	 by	 the	disease.	 The	major	 reason	 behind	 the	 complication	and	 early	 death	 is	 poorly	 managed	 diabetes.	 More	than	21	million	live	births	were	affected	by	diabetes	during	pregnancy	in	2013.[1]	Diabetes	is	a	disease	whose	primary	risk	factors	are	obesity,	 ageing	 and	 poor	 dietary	 habits	 (together	with	 genetics).	 It	 is	 a	 costly	 disease	 because	 it	 is	chronic	 and	 can	 lead	 to	 complications	 that	 require	medical	and	hospital	treatment.	People	who	develop	diabetes	may	live	with	the	disease	for	decades.	With	the	rise	in	inactivity,	obesity	and	ageing.	Type	II	dia-betes	 is	 a	 condition	 of	 elevated	 blood-sugar	 levels.	The	body’s	organs,	the	eyes,	heart,	kidneys,	liver	and	the	brain,	need	a	certain	level	of	blood-sugar	to	work	efficiently.	A	blood-sugar	level	that	is	either	too	high	or	too	low	will	lead	to	the	failure	of	one	or	more	of	the	body’s	organs.	A	consistently	high	blood-sugar	level	can	lead	to	hypertension,	stroke	or	kidney	problems.	Each	complication	requires	specific	treatment.	For	in-stance,	hypertension	is	treated	with	medication	that	helps	to	lower	blood	pressure,	whereas	kidney	prob-lems	may	ultimately	require	dialysis	or	kidney	trans-plant.	 It	 is	easy	to	understand	why	the	treatment	of	diabetes	before	any	of	these	occur	is	essential,	for	the	consequences	are	generally	fatal,	or	at	the	very	least,	highly	 debilitating	 for	 the	 patient.	 Yet	 the	 cost	 of	treating	diabetic	complications	is	non-trivial	for	two	reasons:	1)	diabetes	is	incurable	and	the	patient	will	live	with	the	risk	of	developing	any	of	these	compli-cations	for	decades;	and	2)	the	costs	of	medical	and	hospital	 treatment	 are	 high.	 These	 direct	 costs	 are	coupled	with	 indirect	 costs,	 that	 is,	 the	opportunity	
cost	to	society	of	an	individual	not	being	able	to	work	because	of	her	case	of	diabetes.[2]	
METHODOLOGY	The	 prospective	 observation	 study	was	 carried	 out	for	 over	 a	 period	 of	 6	 months	 commencing	 from	March	2014	to	August	2014	among	inpatients	of	Gen-eral	medicine	and	Nephrology	departments	of	a	ter-tiary	care	referral	hospital	 in	kerala.	The	study	was	approved	by	the	ethics	committee	of	hospital	and	was	certified	 by	 the	 Institutional	 ethics	 committee	 met	and	approved	the	proposal	.All	diabetic	patients	with	inadequate	 glycemic	 control	 are	 included	 in	 this	study.	 An	 observational	 pilot	 study	 was	 conducted	before	the	initiation	of	study.	All	diabetes	mellitus	pa-tient	treated	in	the	Inpatient	department	of	General	medicine	and	Nephrology	department	during	March-August	 2014	were	monitored,	 collect	 relevant	 data	and	entered	into	the	data	sheet.	Based	on	the	inclu-sion	and	exclusion	criteria	of	the	protocol	approved	by	the	IEC,	patients	belonging	to	the	age	group	40-70	of	both	sex	were	selected	and	enrolled	for	the	study.	
Inclusion	criteria:	1.	Male	and	 female	outpatients	with	diabetes	melli-tus.	2.	Patients	in	the	age	group	of	40	to	70	years.	3.	Patients	with	inadequate	glycemic	control.	4.	Duration	of	diabetes	since	5	years	to	35	years.	5.	Diabetes	mellitus	patients	who	are	willing	to	co-op-erate	with	the	study.	6.	Patients	without	any	history	of	psychiatric	disor-ders,	language	and	communication	problems.	
Exclusion	criteria:	1.	Male	and	female	inpatients	without	diabetes	melli-tus.	2.	 Patients	 in	 the	 age	 group	below	40	 and	 above70	years.	3.	Patients	with	adequate	glycemic	control.	4.	Duration	of	diabetes	since	below	5	years	and	above	35	years.	5.	Diabetes	mellitus	patients	who	are	not	willing	 to	co-operate	with	the	study.	6.	Patients	with	any	history	of	psychiatric	disorders,	language	and	communication	problems.	The	data	collection	form	is	used	to	register	the	per-sonal,	family,	disease	and	treatment	details	of	the	en-rolled	 patients.	 It	 contains	 details	 of	 patient’s	 de-mographics	 ,comorbidities,	 duration	 of	 diabetes	mellitus,	 past	 medication	 history	 for	 diabetes,	 dia-betic	microvascular	complications,	family	history,	so-cial	 status,	 occupation,	 annual	 income,	psychosocial	status,	diet,	life	style	and	laboratory	parameters	such	as	BP,FBS,	RBS	,PPBS,	HbA1c,	protein	creatinine	ratio,	
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serum	creatinine	 ,	blood	urea	nitrogen,	 fasting	 lipid	profile,	urinary	albumin/creatinine,	drug	therapy	for	diabetes,	 nephropathy,	 neuropathy	 and	 retinopathy	expenses	incurred	for	treatment	and	all	the	relevant	things	which	are	necessary	for	the	study.	All	the	rele-vant	information	regarding	demographics,	socioeco-nomics	 and	 lifestyle	 characteristics	 (smoking,	 alco-hol,	consumption)	were	collected	by	interviewing	the	patients,	 and	 patient	 care	 givers.	 Anthropometric	measurement	 including	 weight,	 height,	 and	 body	mass	index	were	carried	out	at	the	time	of	admission.	Clinical	 systolic	 BP,	 diastolic	 BP	 level,	 blood	 sugar	level	including	RBS,	FBS,	HbA1C,	lipid	profile,	serum	creatinine,	blood	urea,	urine	analysis	reports	are	ex-tracted	 from	 available	 medical	 record.	 Socioeco-nomic	 status	was	assessed	using	 the	modified	Kup-puswamy’s	 scales,	 which	 consider	 the	 education	qualification,	occupation	of	the	family	head	and	fam-ily	income	per	month	of	the	participant.	For	calculat-ing	 the	 cost	 of	 illness,	 interviewed	 the	 patients	 on	economic	aspect	of	 treatment	which	 includes	direct	medical	 cost	 like	physician	 fee,	 Investigation	 report	charges,	cost	of	drugs,	direct	non-medical	costs	 like	cost	 of	 transportation,	 expense	 incurred	 on	 food,	room	 rent	 on	 time	 of	 hospitalization	 and	 indirect	non-medical	costs	like	patient	per	day	salary	loss	and	bye	stander	wage	loss	if	occurred	to	carry	out	cost	of	illness	 analysis	 diabetes	 mellitus.	 All	 the	 relevant	data	were	collected	in	a	predesighned	paper	case	rec-ord	form	with	prior	consent	of	the	participant.	
RESULTS	AND	DISCUSSION	
Age	wise	distribution	
Table	1:	Age	wise	distribution	cost	of	illness	
Age wise cost of 
illness N Mean 
Std.  
Devia-
tion 
Direct  
medical cost 
45 - 60 22 19852.13 15039.42 
61 - 70 30 21651.13 14726.37 
Direct non 
medical cost 
45 - 60 22 2793.10 1362.56 
61 - 70 30 2983.67 1206.78 
Total cost of 
illness 
45 - 60 22 22645.23 15263.78 
61 - 70 30 24634.80 14835.03 
	
Figure	1;	Age	wise	distribution	cost	of	illness	Out	 of	 52	 patients	 studied	 direct	 medical	 cost	 was	found	to	be	higher	(mean=21651.13	Rs,	standard	de-viation+14726.37)	 in	patient	belongs	 to	61-70	year	age	group.	The	total	cost	of	illness	was	also	higher	in	patient	 with	 this	 age	 group	 (mean=24634.80	 Rs,	standard	deviation=14835.03).	The	patient	belong	to	
this	age	 	group	may	suffered	from	other	comorbidi-ties	and	microvascular	complications,	 so	 the	cost	of	illness	was	 found	 to	 be	 higher	 in	 those	 patients	 as	compared	with	other	age	group.	
Table	2:	sexwise	cost	of	illness	
Sex wise cost  
of illness N Mean 
Std. Devia-
tion 
Direct  
medical 
cost 
Male 28 25743.84 17225.90 
Female 24 15227.22 8441.66 
Direct 
non med-
ical cost 
Male 28 3050.71 1073.48 
Female 24 2730.76 1463.25 
Total cost 
of illness 
Male 28 28794.55 17298.90 
Female 24 17957.98 8667.21 
	
Figure	2:	sex	wise	distribution	
	
Figure	3:	Area	wise	distribution	of	cost	of	illness	
	
Figure	4:	Therapy	wise	distribution	of	cost	of	illness	
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Figure	5:	Socioeconomic	status	
	
Figure	6:	cost	of	illness	of	patients	
Compare	the	cost	of	illness	between	microvascu-
lar	patients	and	non	microvascular	patients.		The	 direct	 medical	 cost	 (mean=35205.18),	 direct	non-medical	cost	(mean	=3180.53)	and	total	cost	of	illness	 (mean=38385.71)	 was	 higher	 in	 diabetic	nephropathy	 (n=19)	 than	 diabetic	 retinopathy	 and	diabetic	neuropathy.	Here	the	P	value	obtained	for	di-rect	cost	and	total	cost	of	illness	was	0.0001,	which	is	a	significant	result.	In	diabetic	retinopathy	the	direct	medical	cost,	direct	non-medical	cost	and	total	cost	of	illness	 obtained	 was	 26361.25,	 3261.43	 and	29622.68	respectively.	Here	the	P	value	obtained	for	total	cost	of	illness	was	0.087,	which	was	not	signifi-cant.	In	diabetic	neuropathy	the	direct	medical	cost,	direct	non-medical	 cost	 and	 total	 cost	of	 illness	ob-tained	 was	 24227.42,	 3428	 and	 27655.42	 respec-tively.	The	P	value	obtained	is	0.141,	which	was	not	significant.	
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Table	3:	Area	wise	distribution	of	cost	of	illness	
Area wise cost of illness N Mean Std. Deviation Std. Error mean 
Direct medical cost Rural 38 22700.03 15908.54 2580.71 Urban 14 15977.11 9820.03 2624.51 
Direct non medical cost Rural 38 2772.85 1255.17 203.62 Urban 14 3256.43 1270.90 339.66 
Total cost of illness Rural 38 25472.88 16056.68 2604.74 Urban 14 19233.54 10331.59 2761.23 
Table	4:	Therapy	wise	distribution	of	cost	of	illness	
Type of therapy N Mean Std. Deviation 
Direct medical cost Insulin only 18 21603.80 9775.33 Insulin+oral drug 34 20512.13 16914.72 
Direct non medical cost Insulin only 18 3297.22 1169.78 Insulin+oral drug 34 2694.36 1280.89 
Cost of illness Insulin only 18 24901.02 9933.31 Insulin+oral drug 34 23206.49 17068.45 
Table	5:	socioeconomic	status	of	patients	
Socioeconomic status Frequency Percent(%) 
Lower middle 14 26.9 
Upper 2 3.8 
Upper lower 25 48.1 
Upper middle 10 19.2 
Upper lower 1 1.9 
Table	6:	cost	of	illness	of	patients	
Cost of illness (in rs) Mean Std. Deviation Minimum Maximum 
Direct medical cost 20890.01 14739.61 5967.45 69451.50 
Direct non medical cost 2903.04 1265.55 500.00 6350.00 
Total cost of illness 23793.06 14901.74 6917.45 73121.50 
	
